CD274 and neoplasm: On the other hand, in trials assessing atezolizumab, PD-L1 expression has been evaluated on immune cells (ICs) using SP142 as the percentage of tumor area infiltrated by PD-L1-positive immune cells relative to the total tumor area [67,68].